Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -7.47
- Piotroski Score 1.00
- Grade Buy
- Symbol (TELA)
- Company TELA Bio, Inc.
- Price $3.05
- Changes Percentage (2.01%)
- Change $0.06
- Day Low $2.91
- Day High $3.17
- Year High $7.84
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. The company markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/07/2024
- Fiscal Year End N/A
- Average Stock Price Target $11.00
- High Stock Price Target $20.00
- Low Stock Price Target $8.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.64
- Trailing P/E Ratio -3.41
- Forward P/E Ratio -3.41
- P/E Growth -3.41
- Net Income $-46,664,000
Income Statement
Quarterly
Annual
Latest News of TELA
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Teladoc Health (TDOC) Q3 2024 Earnings Call Transcript
Teladoc Health reported potential risks that could affect actual results, emphasizing caution. The CEO highlighted strengths to build upon, such as market position and employee talent. Changes in lead...
By Yahoo! Finance | 1 week ago -
Antony Koblish Bought 42% More Shares In TELA Bio
Antony Koblish, Co-founder of TELA Bio, Inc., recently purchased $200k worth of stock at $2.25 per share, increasing his holding by 42%. This significant insider purchase is a positive sign, although ...
By Yahoo! Finance | 1 week ago -
Is Teladoc Health Inc. (TDOC) the Best US Stock to Buy Under $10?
An analysis of Teladoc Health Inc. (NYSE:TDOC) against other US stocks under $10 reveals potential growth in small-cap stocks despite concerns over high valuations. With a focus on diversification bey...
By Yahoo! Finance | 2 weeks ago
